Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients
Status:
Completed
Trial end date:
2021-09-07
Target enrollment:
Participant gender:
Summary
The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological
parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants
should have had at least one stone event within 12 months of screening and intact renal
function.